Hospira

MATERIAL SAFETY DATA SHEET

Product Name: Furosemide Injection

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address	Hospira Inc. 275 North Field Drive Lake Forest, Illinois USA 60045
Emergency Telephone	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia (02) 8014 4880
Hospira, Inc., Non-Emergency	224-212-2000
Product Name	Furosemide Injection
Synonyms	4-chloro-N-furfuryl-5-sulfamoylanthranilic acid

2. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name	Furosemide
Chemical Formula	$C_{12}H_{11}ClN_2O_5S$
Preparation	Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at less than 1% include sodium chloride. Contains sodium hydroxide and may contain hydrochloric acid for pH adjustment.

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Furosemide	1	54-31-9	CB2625000

3. HAZARD INFORMATION

Carcinogen List

Substance	IARC	NTP	OSHA
Furosemide	3	Not Listed	Not Listed

Emergency Overview	Furosemide Injection is a solution containing furosemide, a loop diuretic with a rapid onset of action. It is used in the treatment of edema associated with heart failure, including pulmonary edema, with renal and hepatic disorders, and to treat hypertension. In the workplace, this material should be considered potentially irritating to the eyes and respiratory tract. Based on clinical use, possible target organs include the gastrointestinal system, central nervous system, blood and kidneys.
Occupational Exposure Potential	Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.
Signs and Symptoms	None known from occupational exposure. In clinical use, the most common adverse effect is fluid and electrolyte imbalance including hyponatremia, hypokalemia, and hypochloremic alkalosis, particularly after large doses or prolonged use. Signs of electrolyte imbalance include headache, hypotension, muscle cramps, dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, oliguria, cardiac arrhythmias, pancreatitis, jaundice and other gastrointestinal

disturbances. Hypovolemia and dehydration may occur, especially in the elderly. Furosemide may cause hyperuricemia and precipitate gout in some patients. It may provoke hyperglycemia and glycosuria. Other adverse effects may include blurred vision, yellow vision, dizziness, headache, and orthostatic hypotension. Skin rashes and photosensitivity reactions may be severe; hypersensitivity reactions may include interstitial nephritis and vasculitis; fever has also been reported. Bone marrow depression may occur; there have been reports of agranulocytosis, thrombocytopenia, and leucopenia. Tinnitus and deafness may occur, in particular during rapid high-dose parenteral furosemide.

Medical Conditions Aggravated by Exposure — Pre-existing hypersensitivity to this material; pre-existing kidney or hematological disorders.

4. FIRST AID MEASURES

Eye contact — Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin contact — Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation — Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Ingestion — Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability — None anticipated for this aqueous product.

Fire & Explosion Hazard — None anticipated for this aqueous product.

Extinguishing media — As with any fire, use extinguishing media appropriate for primary cause of fire.

Special Fire Fighting Procedures — No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal — Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling — No special handling required under conditions of normal product use

Storage — No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.

Special Precautions No special precautions required for hazard control.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

	Exposure limits				
Component	**Type**	**mg/m3**	**ppm**	**µg/m3**	**Note**
Furosemide	Not Applicable	N/A	N/A	N/A	None Established

Respiratory protection Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin protection If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye protection Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Liquid
Color	Clear, Colorless
Odor	NA
Odor Threshold:	NA
pH:	9.0 (8.0 - 9.3)
Melting point/Freezing point:	NA
Initial Boiling Point/Boiling Point Range:	NA
Evaporation Rate:	NA
Flammability (solid, gas):	NA
Upper/Lower Flammability or Explosive Limits:	NA
Vapor Pressure:	NA
Vapor Density:	NA
Specific Gravity:	NA
Solubility:	Practically insoluble in water, sparingly soluble in alcohol
Partition coefficient: n-octanol/water:	NA
Auto-ignition temperature:	NA
Decomposition temperature:	NA

10. STABILITY AND REACTIVITY

Reactivity Not determined.

Chemical Stability Stable under standard use and storage conditions.

Hazardous Reactions Not determined.

Conditions to avoid Not determined.

Incompatibilities Not determined.

Hazardous decomposition products Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx), nitrogen oxides (NOx), sulfur oxides (SOx), and hydrogen chloride.

Hazardous Polymerization Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity
Not determined for the product formulation. Information for the ingredients is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Furosemide	100	LD50	Oral	2600 2000 800 2000	mg/kg mg/kg mg/kg mg/kg	Rat Mouse Rabbit Dog
Furosemide	100	LD50	Intravenous	800 308 400 >400	mg/kg mg/kg mg/kg mg/kg	Rat Mouse Rabbit Dog

Aspiration Hazard None anticipated from normal handling of this product.

Dermal Irritation/Corrosion None anticipated from normal handling of this product.

Ocular Irritation/Corrosion None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation.

Dermal or Respiratory Sensitization None anticipated from normal handling of this product. In clinical use, skin rashes and photosensitivity reactions may be severe; hypersensitivity reactions may include interstitial nephritis and vasculitis; fever has also been reported.

Reproductive Effects Furosemide produced no impairment of fertility in male or female rats, at 100 mg/kg/day (the maximum effective diuretic dose in the rat and 8 times the maximal human dose of 600 mg/day). The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits. Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (2 times the maximal recommended human oral dose of 600 mg/day). In another study, a dose of 50 mg/kg (4 times the maximal recommended human oral dose of 600 mg/day) also caused maternal deaths and abortions when administered to rabbits between Days 12

	and 17 of gestation. In a third study, none of the pregnant rabbits survived an oral dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths. The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses derived from treated dams as compared with the incidence in fetuses from the control group. FDA Pregnancy Category C: Furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits at 2, 4, and 8 times the maximal recommended human oral dose.
Mutagenicity	Furosemide was devoid of mutagenic activity in various strains of Salmonella typhimurium when tested in the presence or absence of an in vitro metabolic activation system, and questionably positive for gene mutation in mouse lymphoma cells in the presence of rat liver S9 at the highest dose tested. Furosemide did not induce sister chromatid exchange in human cells in vitro, but other studies on chromosomal aberrations in human cells in vitro gave conflicting results. In Chinese hamster cells it induced chromosomal damage but was questionably positive for sister chromatid exchange. Studies on the induction by furosemide of chromosomal aberrations in mice were inconclusive. The urine of rats treated with this drug did not induce gene conversion in Saccharomyces cerevisiae.
Carcinogenicity	Furosemide was tested for carcinogenicity by oral administration in one strain of mice and one strain of rats. A small but significantly increased incidence of mammary gland carcinomas occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg. There were marginal increases in uncommon tumors in male rats at a dose of 15 mg/kg (slightly greater than the maximum human dose) but not at 30 mg/kg.
Target Organ Effects	Based on clinical use, possible target organs include the gastrointestinal system, central nervous system, blood and kidneys.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for product.
Persistence/Biodegradability	Not determined for product.
Bioaccumulation	Not determined for product
Mobility in Soil	Not determined for product.

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS: Not regulated

IMDG STATUS: Not regulated

ICAO/IATA STATUS: Not regulated

Transport Comments: None

15. REGULATORY INFORMATION

USA Regulations

Substance	TSCA Status	CERCLA Status	SARA 302 Status	SARA 313 Status	PROP 65 Status
Furosemide	Not Listed	Not Listed	Not Listed	Not Listed	Not Listed

RCRA Status Not Listed
U.S. OSHA Target Organ Toxin
Classification Possible Irritant

GHS Classification *In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user:

Hazard Class Not Applicable

Hazard Category Not Applicable

Signal Word Not Applicable

Symbol Not Applicable

Prevention P260 - Do not breathe dust/fume/gas/mist/vapors/spray.

Hazard Statement Not Applicable

Response: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. Wash hands after handling.

Get medical attention if you feel unwell

EU Classification*
*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive. Information provided below is for the pure drug substance Furosemide

Classification(s): Not Applicable

Symbol: Not Applicable

Indication of Danger: Not Applicable

Risk Phrases: Not Applicable

Safety Phrases: S23 - Do not breathe vapor.
S24/25 - Avoid contact with skin and eyes.
S37/39 - Wear suitable gloves and eye/face protection.

16. OTHER INFORMATION:

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD50	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS
Date Prepared: 09/23/2011
Obsolete Date: 10/21/2008

Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.